Published evidence indicates the value of repetitive tran-scranial magnetic stimulation (rTMS) for generalized anxiety disorder in patients with treatment-resistant depression (TRD). As a part of routine clinical service, patients with TRD received right dorsolateral prefrontal cortex (DLPFC) inhibitory rTMS immediately prior to left DLPFC depression treatment delivered according to a US Food and Drug Administration protocol.
Methods
A retrospective investigation of routinely collected data between 2016 and 2018 was undertaken. Measures used were the clinicianrated Clinical Global Impressions-Severity (CGI-S) scale and Hamilton Depression Rating scale (HAM-D), and the patient-rated Generalized Anxiety Disorder scale-7 (GAD-7) and Patient Health Questionnaire (PHQ-9). The outcome data of 61 patients with TRD were analyzed. The sample included patients with comorbid psychiatric diagnoses.
Results
Response and remission rates, respectively, were 17.1% and 27.3% on the GAD-7; 20.7% and 12.5% on the HAM-D; 19% and 24% on the PHQ-9; and 20% and 23.5% on the CGI-S. Post-treatment scores significantly improved on the GAD-7, HAM-D, and CGI-S scales, with medium to large effect sizes (.61, .62, and .86 respectively).
Conclusions
Results indicate the potential value of rTMS in treating anxiety in patients who are referred for rTMS for TRD. Well-designed and adequately powered randomized controlled trials are required to determine clinical recommendations.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association.Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2.
World Health Organization.Depression and other common mental disorders: global health estimates. Geneva, Switzerland: World Health Organization; 2017.
3.
KesslerRCWangPS.The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health.2008; 29: 115–129.
4.
MichaelTZetscheUMargrafJ.Epidemiology of anxiety disorders. Psychiatry.2007; 6: 136–142.
5.
RevickiDATraversKWyrwichKWHumanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord.2012; 140: 103–112.
6.
YoungSPfaffDLewandowskiKEAnxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology.2013; 46: 176–185.
7.
KarpovBJoffeGAaltonenKAnxiety symptoms in a major mood and schizophrenia spectrum disorders. Eur Psychiatry.2016; 37: 1–7.
8.
SchomerusGSchwahnCHolzingerAEvolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand.2012; 125: 440–452.
9.
BandelowBBoernerJRKasperSThe diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int.2013; 110: 300–309; quiz 310.
10.
BespalovAYvan GaalenMMGrossG.Antidepressant treatment in anxiety disorders. In: Stein MB, Steckler T, eds. Behavioral neurobiology of anxiety and its treatments.New York: Springer; 2010: 361–390.
11.
LingamRScottJ.Treatment non-adherence in affective disorders. Acta Psychiat Scand.2002; 105: 164–172.
12.
SwansonJFSwartzMSWagnerHRInvoluntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. Br J Psychiatry.2000; 176: 324–331.
13.
DaviesJReadJ.A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?Addict Behav.2018; pii: S0306–4603 (18)30834-7. doi: 10.1016/j.addbeh.2018.08.027.
14.
National Institute for Health and Care Excellence.Generalised anxiety disorder and panic disorder in adults: management. http://www.nice.org.uk/guidance/cg113. Published January 2011. Accessed June 6, 2018.
15.
GyaniAShafranRLayardREnhancing recovery rates: lessons from year one of IAPT. Behav Res Ther.2013; 51: 597–606.
16.
GriffithsCAGriffithsLJ.Recovery and reliable change rates for patients scoring severe on depression, anxiety or impaired functioning in a psychological therapies service: IAPT. Ment Health Rev J.2014; 20: 28–35.
17.
LindsayWRGamsuCVMcLaughlinEA controlled trial of treatments for generalized anxiety. Br J Clin Psychol.1987, 26(pt 1):3–15.
18.
PowerKGSimpsonRJSwansonVControlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract.1990; 40: 289–294.
19.
HardySBastickLO'Neill-KerrATranscranial magnetic stimulation in clinical practice. BJ Psych Advances.2016; 22: 373–379.
20.
JanicakPGDokucuME.Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat.2015; 11: 1549–1560.
21.
FoyJR.Cerena transcranial magnetic stimulator: evaluation of automatic class III designation - de novo request. Food and Drug Administration.https://www.accessdata.fda.gov/cdrh_docs/pdf13/K130556.pdf. Published December 13, 2013. Accessed June 6, 2019.
22.
National Institute for Health and Care Excellence.Repetitive transcranial magnetic stimulation for depression. https://www.nice.org.uk/guidance/ipg542. Published December 2015. Accessed June 6, 2019.
23.
Leon-SarmientoFEGranadilloEBayonaEA.Present and future of the transcranial magnetic stimulation [in Spanish]. Invest Clin.2013; 54: 74–89.
24.
PaesFMachadoS, Arias-CarrionOThe value of repetitive transcranial magnetic stimulation (rTMS) for the treatment of anxiety disorders: an integrative review. CNS Neurol Disord Drug Targets.2011; 10: 610–620.
25.
MachadoSPaesFVelasquesBIs rTMS an effective therapeutic strategy that can be used to treat anxiety disorders?Neuropharmacology.2012; 62: 125–134.
26.
MochcovitchMDda RochaFreire RCGarciaRFA systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. J Affect Disord.2014; 167: 336–342.
27.
HilbertKLuekenUBeesdo-BaumK.Neural structures, functioning and connectivity in generalized anxiety disorder and interaction with neuroendocrine systems: a systematic review. J Affect Disord.2014; 158: 114–126.
BagbyRMRyderAGSchullerDRThe Hamilton Depression Rating Scale: has the gold standard become a lead weight?Am J Psychiatry.2004; 161: 2163–2177.
30.
GuyW.ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare;1976;534–537.
31.
ForkmannTSchererABoeckerMThe clinical global impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry.2011; 11: 83.
32.
KroenkeKSpitzerRLWilliamsJB.The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med.2001; 16: 606–613.
33.
SpitzerRLKroenkeKWilliamsJBWA brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med.2006; 166: 1092–1097.
34.
KroenkeKSpitzerRLWilliamsJBAnxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med.2007; 146: 317–325.
35.
TsuzukiDWatanabeHDanIMinR 10/20 system: Quantitative and reproducible cranial landmark setting method for MRI based on minimum initial reference points. J Neurosci Methods.2016; 264: 86–93.
36.
Food and Drug Administration.Class II special controls guidance document: repetitive transcranial magnetic stimulation (rTMS) systems - guidance for industry and FDA staff. Rockville, MD: US Department of Health and Human Service; 2011.
37.
HadleyDAndersonBSBorckardtJJSafety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. J ECT.2011; 27: 18–25.
38.
DilkovDHawkenERKaludievERepetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry.2017; 1: 61–65.
39.
Health Quality Ontario.Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser.2016; 16: 1–66.
40.
ConnollyKRHelmerACristanchoMAEffectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry.2012; 73: e567–e573.
41.
GalletlyCAClarkePCarnellBLA clinical repetitive transcranial magnetic stimulation service in Australia: 6 years on. Aust N Z J Psychiatry.2015; 49: 1040–1047.
42.
DiefenbachGJBragdonLGoetheJW.Treating anxious depression using repetitive transcranial magnetic stimulation. J Affect Disord.2013; 151: 365–368.
43.
LaSalle-RicciVHSiskoEDeBlasioKEarly improvement of depression and anxiety symptoms with repetitive transcranial magnetic stimulation (rtms) augmentation of medication: case series. Brain Stimul.2014; 7: e20–e21.
44.
CaulfieldKAKetchabawWTPascual-LeoneAReductions in depression and anxiety measures are correlated in patients receiving transcranial magnetic stimulation. Brain Stimulation.2016; 9: e1–e9.
45.
WhiteDTavakoliS.Repetitive transcranial magnetic stimulation for treatment of major depressive disorder with comorbid generalized anxiety disorder. Ann Clin Psychiatry.2015; 27: 192–196.
46.
CressK.A retrospective analysis of transcranial magnetic stimulation right dorsolateral prefrontal cortex treatments for patients with generalized anxiety disorder. Brain Stimul.2016; 9: e1–e9.
47.
DiefenbachGJBragdonLBZertucheLRepetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial. Br J Psychiatry.2016; 209: 222–228.
48.
HuangZLiYZhanSLiN. P1060: Suppressing cortical hyperexcitability of right parietal cortex by repetitive transcranial magnetic stimulation (rTMS) relieved the anxiety symptom of patients with generalized anxiety disorder. Clin Neurophysiol.2014; 125: S278.
49.
HuangZLiYBianchiMTRepetitive transcranial magnetic stimulation of the right parietal cortex for comorbid generalized anxiety disorder and insomnia: a randomized, double-blind, sham-controlled pilot study. Brain Stimul.2018; 11: 1103–1109.
50.
EngelsASHellerWSpielbergJMCo-occurring anxiety influences patterns of brain activity in depression. Cogn Affect Behav Neurosci.2010; 10: 141–156.
51.
BruderGEFongRTenkeCERegional brain asymmetries in major depression with or without an anxiety disorder: a quantitative electroencephalographic study. Biol Psychiatry.1997; 41: 939–948.
52.
MoonCMKangHKJeongGW.Metabolic change in the right dorsolateral prefrontal cortex and its correlation with symptom severity in patients with generalized anxiety disorder: Proton magnetic resonance spectroscopy at 3 Tesla. Psychiatry Clin Neurosci.2015; 69: 422–430.
53.
SanchezAVanderhasseltMABaekenCEffects of tDCS over the right DLPFC on attentional disengagement from positive and negative faces: an eye-tracking study. Cogn Affect Behav Neurosci.2016; 16: 1027–1038.
54.
SchmidtCKKhalidSLoukasMNeuroanatomy of anxiety: a brief review. Cureus.2018; 10: e2055. doi: 10.7759/cureus.2055.
55.
KitoSFujitaKKogaY.Changes in regional cerebral blood flow after repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in treatment-resistant depression. J Neuropsychiatry Clin Neurosci.2008; 20: 74–80.
BaekenCDe RaedtR.Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci.2011; 13: 139–145.
58.
KozelFA.Clinical repetitive transcranial magnetic stimulation for posttraumatic stress disorder, generalized anxiety disorder, and bipolar disorder. Psychiatr Clin North Am.2018; 41: 433–446.
